Skip to content
Wednesday, August 26, 2026
1 WOMEN'S HEALTHWOMEN'S & REPRODUCTIVE HEALTH

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.

Records
5,000
Last changed
Update schedule
55 1 * * * UTC
Coverage
05/26/2000–08/25/2026
Method
Methodology
Title
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
Record Date
06/30/2015
Vuga Group
INTERVENTIONAL
Change Status
unchanged
Recency Days
4,075.85
Public Significance Score
0